US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
MSTR
$160.01
▲+0.00%
ASML
$1,867.31
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
MSTR
$160.01
▲+0.00%
ASML
$1,867.31
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Akero Therapeutics Inc.
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
November 07, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
October 09, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
October 07, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
August 28, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
August 14, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 08, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 03, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
May 28, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
May 10, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
May 09, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
May 09, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
May 07, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
April 30, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 28, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 30, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
January 28, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces Proposed Public Offering of Common Stock
January 27, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
January 27, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
January 13, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
November 26, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
November 15, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
November 13, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 08, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
October 21, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
September 30, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
September 09, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Tickers
AKRO
